

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

29 May 2026

### Comparison of the effect of Neostigmine and Metoclopramide on gastric residual volume in mechanically ventilated ICU patients

#### Protocol summary

gholipourafshin@mazums.ac.ir

#### Summary

The aim of this double blind randomized clinical trial is to compare the effect of Metoclopramide and Neostigmine on gastric residual volume in mechanically ventilated ICU patients. 60 patients, who are qualified for study entry, randomly allocate in two equal 30patients intervention groups. The first group receives 2.5mg Neostigmine and the second group receives 10 mg Metoclopramide in 100 cc Normal Saline which infused at 30 minutes. Then gastric residual volume will be checked 0, 3, 6, 9 and 12 hours after intervention. Also Heart rate, Blood pressure, Na, K, Mg, Hb, WBC, Albumin and SOFA are measured before intervention. After collecting and classifying of information, data will be analyzed with SPSS19.

#### Recruitment status

**Recruitment complete**

#### Funding source

Mazandaran University of Medical Sciences

#### Expected recruitment start date

2013-02-01, 1391/11/13

#### Expected recruitment end date

2014-02-01, 1392/11/12

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### General information

#### Acronym

#### IRCT registration information

IRCT registration number: **IRCT201412044365N18**

Registration date: **2014-12-17, 1393/09/26**

Registration timing: **retrospective**

Last update:

Update count: **0**

#### Registration date

2014-12-17, 1393/09/26

#### Registrant information

#### Name

Afshin Gholipour Baradari

#### Name of organization / entity

Mazandaran University of Medical Sciences

#### Country

Iran (Islamic Republic of)

#### Phone

+98 11 3326 1245

#### Email address

#### Scientific title

Comparison of the effect of Neostigmine and Metoclopramide on gastric residual volume in mechanically ventilated ICU patients

#### Public title

Comparison of the effect of Neostigmine and Metoclopramide on gastric residual volume in mechanically ventilated ICU patients

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

Inclusion criteria: patient family agreement and informed written consent; under mechanical ventilation; nutrition via gastric tube; gastric residual volume greater than 120 cc; age between 20 and 70 years Exclusion criteria: diabetes; heart rate<60; heart blocks and arrhythmias; systolic BP less 90 mmHg; hypothermia (core temperature less 35); renal failure (Serum Creatinin more 1.5 in two consecutive test); prokinetic agents consumption during 8 hours before intervention; recent surgery on GI tract within 10 days; pregnancy and breast feeding; extrapyramidal sign; bronchospasm; hypokalemia (K less 3 meq/L); known sensitivity to

Neostigmine and metoclopramide; GI bleeding

### Age

From **20 years** old to **70 years** old

### Gender

Both

### Phase

2-3

### Groups that have been masked

*No information*

### Sample size

Target sample size: **60**

### Randomization (investigator's opinion)

Randomized

### Randomization description

### Blinding (investigator's opinion)

Double blinded

### Blinding description

### Placebo

Not used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

ethic committee of Mazandaran University of Medical Sciences

##### Street address

Mazandaran University of Medical Sciences, Moallem Square

##### City

Sari

##### Postal code

46175866

#### Approval date

2013-01-30, 1391/11/11

#### Ethics committee reference number

91-204

## Health conditions studied

### 1

#### Description of health condition studied

gastric residual volume

#### ICD-10 code

K31.0

#### ICD-10 code description

acute dilatation of stomach

## Primary outcomes

### 1

#### Description

gastric residual volume

#### Timepoint

0,3,6,9,12 hours after intervention

#### Method of measurement

Gastric lavage

## Secondary outcomes

### 1

#### Description

Albumin, Hemoglobin, WBC, Na, K, Mg

#### Timepoint

before trial

#### Method of measurement

laboratory kit

### 2

#### Description

hear rate, blood pressure

#### Timepoint

during trial

#### Method of measurement

cardiac monitoring

### 3

#### Description

SOFA

#### Timepoint

before trial

#### Method of measurement

SOFA calculator

## Intervention groups

### 1

#### Description

Intrvention group 1: Neostigmine 2.5 mg in 100 ml normal saline infused during 30 minute at the beginning of trial.

#### Category

Treatment - Drugs

### 2

#### Description

Intrvention group 2: Metoclopramide 10 mg in 100 ml normal saline infused during 30 minute at the beginning of trial.

#### Category

Treatment - Drugs

## Recruitment centers

## 1

### Recruitment center

**Name of recruitment center**

Imam Khomeini General Hospital

**Full name of responsible person**

Afshin Gholipour Baradari, MD, CCMF, Associate Professor

**Street address**

Imam Khomeini general Hospital, Amir St.

**City**

Sari

Sari

**Postal code**

48175-866

**Phone**

+98 11 3326 2679

**Fax****Email**

gholipourafshin@mazums.ac.ir;  
gholipourafshin@yahoo.com

**Web page address**

www.mazums.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Vice chancellor for research of Mazandaran University of Medical Sciences

**Full name of responsible person**

Ahmad Ali Enayati, MD

**Street address**

Mazandaran University of Medical Sciences, Moallem Square- Sari- Iran

**City**

Sari

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor for research of Mazandaran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Afshin Gholipour Baradari, MD

**Position**

CCMF, Associate Professor, Chief of ICU

**Other areas of specialty/work****Street address**

Mazandaran University of Medical Sciences, Moallem Square, Sari, Iran

**City**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Afshin Gholipour Baradari, MD

**Position**

CCMF, Associate Professor, Chief of ICU

**Other areas of specialty/work****Street address**

Mazandaran University of Medical Sciences, Moallem Square

**City**

Sari

**Postal code****Phone**

+98 11 3326 2679

**Fax****Email**

gholipourafshin@mazums.ac.ir;  
gholipourafshin@yahoo.com

**Web page address**

www.mazums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Abolfazl Firouzian, MD

**Position**

Assistant Professor

**Other areas of specialty/work****Street address**

Mazandaran University of Medical Sciences, Moallem Square

**City**

Sari

**Postal code**

48175-866

**Phone**

+98 11 3326 2679

**Fax****Email**

ab.firouzian@gmail.com

**Web page address**

www.mazums.ac.ir

## **Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*